Boston Pharmaceuticals Inc.
Industry
- Biotechnology
- Pharmaceuticals
Latest on Boston Pharmaceuticals Inc.
In the non-alcoholic steatohepatitis (NASH) space, Novo Nordisk was the star of the 2024 American Association for the Study of Liver Disease meeting with additional data from its Phase III study of se
A cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the
With three Phase III studies underway for efruxifermin in metabolic-associated steatohepatitis (MASH), Akero Therapeutics, Inc. used the recent European Association for the Study of Liver Disease an
Madrigal Pharmaceuticals, Inc. ’s Rezdiffra (resmetirom) has become the first ever approved therapy for metabolic-associated steatohepatitis (MASH). The company has a lead of a couple of years over it